Skip to main content
. 2016 Feb 23;53:210–219. doi: 10.1007/s12020-016-0895-8

Fig. 1.

Fig. 1

Effect of pasireotide LAR and active control on a GH, b IGF-1, c IGFBP-3, and d IGFBP-2 levels during 24 weeks of treatment in all patients, responders, and non-responders. Data presented as geometric mean and 68 % CI. Inset values represent patient numbers at 24 weeks